Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072500 | 0.93 | MAPT (0.40) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072319 | 0.92 | HTT (0.36) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072467 | 0.91 | MAPT (0.42) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072110 | 0.90 | CASP1 (0.35) | MAPTGAALMNAADRB2HTT | |
| SCHEMBL6072216 | 0.90 | MAPT (0.38) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| Hydrochloric Acid SCHEMBL6072215 | 0.89 | MAPT (0.42) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072353 | 0.89 | MAPT (0.41) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072285 | 0.89 | MAPT (0.41) | MAPTSMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL6072312 | 0.89 | KDM4E (0.40) | MAPTGAALMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6072326 | 0.88 | MAPT (0.39) | MAPTSMN1; SMN2GAALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | MAPT 4861/4885SMN1; SMN2 4490/4885GAA 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.